Relmada Therapeutics, Inc. (RLMD)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Sergio Traversa M.B.A., Pharm.D.
|
CEO & Director | 3.94M | -- | 1960 |
|
Mr. Maged S. Shenouda M.B.A., R.Ph.
|
Chief Financial Officer | 2.64M | -- | 1964 |
|
Mr. Paul E. Kelly M.B.A.
|
COO & Director | 1.96M | -- | 1957 |
|
Mr. Charles S. Ence CPA, M.B.A.
|
Chief Accounting & Compliance Officer | 2.17M | -- | 1965 |
|
Ms. Gina DiGuglielmo
|
VP & Head of Clinical Operations | -- | -- | -- |
|
Dr. Bipin K. Dalmia MBA, Ph.D.
|
Chief Business Officer | -- | -- | -- |
|
Dr. Andrew Cutler
|
Senior Clinical Development Advisor | -- | -- | -- |
|
Dr. Richard M. Mangano Ph.D.
|
Consultant | -- | -- | 1950 |
Relmada Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 17
Description
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Corporate Governance
Upcoming Events
November 12, 2026 at 9:00 PM UTC
Relmada Therapeutics, Inc. Earnings Date
Recent Events
April 7, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
